Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals
…More; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
